

TECHNICAL DATA SHEET

CyFlow™ CD23 PE Anti-Hu; Clone EBVCS-5

REF AQ467307

For Research Use Only.
Not for use in diagnostic or therapeutic procedures.

Specifications

Antigen	CD23
Alternative Names	FcεRII , BLAST-2
Clone	EBVCS-5
Clonality	monoclonal
Format	PE
Host / Isotype	Mouse / IgG1
Species Reactivity	Human
Negative Species Reactivity	—
Quantity	100 tests
Immunogen	EBV-transformed human cells

Specificity

The mouse monoclonal antibody EBVCS-5 recognizes an epitope located in the stalk region of human low affinity IgE receptor (CD23) between the 37 and 25 kDa cleavage sites.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

Application

The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10 µl reagent / 100 µl of whole blood or 10⁶ cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.

Other usages may be determined from the scientific literature.

Storage Buffer

The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.1% (w/v) sodium azide.

Storage and Stability

Storage	Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
Stability	Do not use after expiration date stamped on vial label.

Background Information

CD23 (Fc ε RII), the low affinity IgE receptor, is a 45 kDa type II membrane glycoprotein expressed more or less on eosinophils, follicular dendritic cells, Langerhans cells, mature B cells (mainly upon activation), EBV-transformed lymphoblasts, monocytes, and subpopulation of platelets. A soluble form of 37 kDa and other its fragments were also described. CD23 mediates IgE-dependent cytotoxicity by eosinophils and macrophages, and downregulates IgE secretion in response to high levels of IgE, involving release of pro-inflammatory cytokines.

References

- Ling NR, Stevenson FK, Brown B: Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 1991 Dec; 86(3):360-6. < PMID: 1721010 >
- Yamaoka KA, Arock M, Issaly F, Dugas N, Le Goff L, Kolb JP: Granulocyte macrophage colony stimulating factor induces Fc epsilon RII/CD23 expression on normal human polymorphonuclear neutrophils. Int Immunol. 1996 Apr; 8(4):479-90. < PMID: 8722638 >
- Rumi C, Rutella S, Leone G, Bonini S: Fc-RII/CD23 receptor on circulating human eosinophils. Blood. 1998 Apr 1; 91(7):2621-2. < PMID: 9516167 >

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

- Belleau JT, Gandhi RK, McPherson HM, Lew DB: Research upregulation of CD23 (FcepsilonRII) expression in human airway smooth muscle cells (huASMC) in response to IL-4, GM-CSF, and IL-4/GM-CSF. Clin Mol Allergy. 2005 May 20; 3:6. < PMID: 15907205 >
- Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S: Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 1; 13(15-1):4448-55. < PMID: 17671129 >

The Safety Data Sheet for this product is available at www.sysmex-partec.com/services.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com